Thomas F X O'Donnell1, Sarah E Deery1, Katie E Shean2, Murray A Mittleman3, Jeremy D Darling4, Mohammad H Eslami5, Randall R DeMartino6, Marc L Schermerhorn7. 1. Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Department of Surgery, Massachusetts General Hospital, Boston, Mass. 2. Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Department of Surgery, St. Elizabeth's Medical Center, Boston, Mass. 3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Mass; Cardiovascular Epidemiology Research Unit, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Mass. 4. Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, Mass. 5. Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa. 6. Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn. 7. Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, Mass. Electronic address: mscherm@bidmc.harvard.edu.
Abstract
BACKGROUND: Although preoperative and perioperative statin therapy improves postoperative outcomes in several populations, few data examine its association with survival after abdominal aortic aneurysm (AAA) repair. In addition, no data exist regarding the benefits of starting statins in patients with AAA not currently taking them. METHODS: We performed a registry-based study of all patients undergoing repair of AAAs in the Vascular Quality Initiative between 2003 and 2017 without documented statin intolerance. In our primary analysis, we evaluated the association between preoperative statin therapy and long-term mortality, 30-day mortality, and in-hospital myocardial infarction and stroke. As a secondary analysis, we studied the cohort of patients not taking a statin preoperatively and compared their long-term mortality on the basis of whether they were discharged on a statin. To account for nonrandom assignment to treatment, we constructed propensity scores and applied inverse probability weighting. RESULTS: We identified 40,452 AAA repairs, of which 37,950 fit our entry criteria (29,257 endovascular and 8693 open). Overall, 25,997 patients (69%) were taking a statin preoperatively, with patients undergoing endovascular aneurysm repair more frequently taking a statin than those undergoing open repair (69% compared with 66%; P < .001). After propensity weighting, preoperative statin therapy was not associated with 30-day death or in-hospital stroke or myocardial infarction. However, patients taking statins preoperatively experienced higher adjusted 1-year (94% vs 90%) and 5-year (85% vs 81%) survival from the date of surgery compared with those who were not (P < .001 overall), although subgroup analysis showed that this applied only to intact or symptomatic aneurysms. Of the 11,941 patients not taking a statin preoperatively and discharged alive, 2910 (24%) started on a statin before discharge. In our secondary analysis of the subset of patients not taking statins preoperatively, those initiated on a statin before discharge experienced higher survival at 1 year (94% vs 91%) and 5 years (89% vs 81%; P < .001 overall) than those who remained off statin therapy, with the greatest absolute long-term survival difference in patients with rupture (87% vs 62%; P < .001 overall). CONCLUSIONS: Preoperative statin therapy is associated with higher long-term survival but not perioperative mortality and morbidity in patients undergoing AAA repair, and initiating statin therapy in previously statin-naive patients is associated with markedly higher survival. All patients with AAAs without contraindications should receive statin therapy. In patients not taking a statin at the time of AAA repair, clinicians should consider initiating one before discharge.
BACKGROUND: Although preoperative and perioperative statin therapy improves postoperative outcomes in several populations, few data examine its association with survival after abdominal aortic aneurysm (AAA) repair. In addition, no data exist regarding the benefits of starting statins in patients with AAA not currently taking them. METHODS: We performed a registry-based study of all patients undergoing repair of AAAs in the Vascular Quality Initiative between 2003 and 2017 without documented statin intolerance. In our primary analysis, we evaluated the association between preoperative statin therapy and long-term mortality, 30-day mortality, and in-hospital myocardial infarction and stroke. As a secondary analysis, we studied the cohort of patients not taking a statin preoperatively and compared their long-term mortality on the basis of whether they were discharged on a statin. To account for nonrandom assignment to treatment, we constructed propensity scores and applied inverse probability weighting. RESULTS: We identified 40,452 AAA repairs, of which 37,950 fit our entry criteria (29,257 endovascular and 8693 open). Overall, 25,997 patients (69%) were taking a statin preoperatively, with patients undergoing endovascular aneurysm repair more frequently taking a statin than those undergoing open repair (69% compared with 66%; P < .001). After propensity weighting, preoperative statin therapy was not associated with 30-day death or in-hospital stroke or myocardial infarction. However, patients taking statins preoperatively experienced higher adjusted 1-year (94% vs 90%) and 5-year (85% vs 81%) survival from the date of surgery compared with those who were not (P < .001 overall), although subgroup analysis showed that this applied only to intact or symptomatic aneurysms. Of the 11,941 patients not taking a statin preoperatively and discharged alive, 2910 (24%) started on a statin before discharge. In our secondary analysis of the subset of patients not taking statins preoperatively, those initiated on a statin before discharge experienced higher survival at 1 year (94% vs 91%) and 5 years (89% vs 81%; P < .001 overall) than those who remained off statin therapy, with the greatest absolute long-term survival difference in patients with rupture (87% vs 62%; P < .001 overall). CONCLUSIONS: Preoperative statin therapy is associated with higher long-term survival but not perioperative mortality and morbidity in patients undergoing AAA repair, and initiating statin therapy in previously statin-naive patients is associated with markedly higher survival. All patients with AAAs without contraindications should receive statin therapy. In patients not taking a statin at the time of AAA repair, clinicians should consider initiating one before discharge.
Authors: Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert Journal: Circulation Date: 2002-07-16 Impact factor: 29.690
Authors: Elliot L Chaikof; David C Brewster; Ronald L Dalman; Michel S Makaroun; Karl A Illig; Gregorio A Sicard; Carlos H Timaran; Gilbert R Upchurch; Frank J Veith Journal: J Vasc Surg Date: 2009-10 Impact factor: 4.268
Authors: R Durieux; H Van Damme; N Labropoulos; A Yazici; V Legrand; A Albert; J-O Defraigne; N Sakalihasan Journal: Eur J Vasc Endovasc Surg Date: 2014-01-20 Impact factor: 7.069
Authors: George A Antoniou; Shahin Hajibandeh; Shahab Hajibandeh; Srinivasa Rao Vallabhaneni; John A Brennan; Francesco Torella Journal: J Vasc Surg Date: 2014-12-10 Impact factor: 4.268
Authors: James C Iannuzzi; Aaron S Rickles; Kristin N Kelly; Aaron E Rusheen; James G Dolan; Katia Noyes; John R T Monson; Fergal J Fleming Journal: Surgery Date: 2013-11-21 Impact factor: 3.982
Authors: Kristina A Giles; Frank Pomposelli; Allen Hamdan; Mark Wyers; Ami Jhaveri; Marc L Schermerhorn Journal: J Vasc Surg Date: 2009-01-09 Impact factor: 4.268
Authors: P Michael Ho; David J Magid; Susan M Shetterly; Kari L Olson; Thomas M Maddox; Pamela N Peterson; Frederick A Masoudi; John S Rumsfeld Journal: Am Heart J Date: 2008-04 Impact factor: 4.749
Authors: Jorg L de Bruin; Annette F Baas; Martijn W Heymans; Mathijs G Buimer; Monique Prinssen; Diederick E Grobbee; Jan D Blankensteijn Journal: J Vasc Surg Date: 2013-10-18 Impact factor: 4.268
Authors: Konrad Salata; Muzammil Syed; Mohamad A Hussain; Charles de Mestral; Elisa Greco; Muhammad Mamdani; Jack V Tu; Thomas L Forbes; Deepak L Bhatt; Subodh Verma; Mohammed Al-Omran Journal: J Am Heart Assoc Date: 2018-10-02 Impact factor: 5.501